Kinnate Biopharma (KNTE) News

Kinnate Biopharma (KNTE): $5.76

0.25 (+4.54%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KNTE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 384

in industry

Filter KNTE News Items

KNTE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

KNTE News Highlights

  • For KNTE, its 30 day story count is now at 3.
  • Over the past 22 days, the trend for KNTE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about KNTE are DRUG.

Latest KNTE News From Around the Web

Below are the latest news stories about KINNATE BIOPHARMA INC that investors may wish to consider to help them evaluate KNTE as an investment opportunity.

Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates

Announced Phase 1 monotherapy dose escalation data for investigational pan-RAF inhibitor exarafenib (KIN-2787) was selected for an oral presentation at the American Association for Cancer Research 2023 Annual MeetingAnnounced the company has initiated enrollment of patients into the monotherapy expansion cohorts evaluating exarafenib Announced the U.S. Food and Drug Administration granted Fast Track designation for KIN-3248, our investigational pan-FGFR inhibitor Cash, cash equivalents and inves

Yahoo | March 15, 2023

Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting

Company has initiated enrollment of patients into the monotherapy expansion cohorts Company to host a virtual investor webcast on April 17, 2023, to discuss the AACR results and dose expansion strategy, and to provide additional pipeline updates SAN FRANCISCO and SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that a clinical trial abstract for its investigational pan-RAF inhibitor exara

Yahoo | March 14, 2023

Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China

Kinnate to retain Kinnjiu’s cash, intellectual property and other assets, including key personnel and legal entity structureKinnate’s cash runway still expected to fund current operations into mid-2024Trial sites open in People's Republic of China (PRC) and Taiwan for ongoing Phase 1 clinical trial evaluating exarafenib, a pan-RAF inhibitorKinnate to maintain strategic presence in PRC, Hong Kong, Macau and Taiwan SAN FRANCISCO and SAN DIEGO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma In

Yahoo | February 21, 2023

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor

SAN FRANCISCO and SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kinnate’s investigational pan-FGFR inhibitor, KIN-3248, for the treatment of patients with unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other

Yahoo | February 14, 2023

Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference

SAN FRANCISCO and SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 1:40 p.m. ET / 10:40 a.m. PT. Members of the Kinnate management team will also host investor meetings during the conference. Investors and the general public a

Yahoo | February 6, 2023

Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director

SAN FRANCISCO and SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its board of directors has appointed a new independent director, Jill DeSimone, who will join effective March 1, 2023. Ms. DeSimone brings more than forty years of global business expertise in life sciences to Kinnate’s board of directors. Dean J. Mitchell, chairman of the Kinnate board of directors, commented, “I am h

Yahoo | January 26, 2023

Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium

SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation of the design and rationale of a Phase 1 trial-in-progress (KN-4802, NCT05242822) evaluating the Company’s investigational pan-FGFR inhibitor, KIN-3248, at two upcoming American Society of Clinical Oncology (ASCO)-related conferences. KIN-3248 is an irreversible, small molecule pan-FGFR inhibitor des

Yahoo | January 17, 2023

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | January 12, 2023

Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates

Cash, cash equivalents and investments of $262.1 million as of September 30, 2022; cash runway expected to fund operations into mid-2024 SAN FRANCISCO and SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced financial results for the quarter ended September 30, 2022, and recent corporate updates. “We continue to make advances with our proprietary programs, and are encouraged by what we’re seei

Yahoo | November 10, 2022

Can Kinnate Biopharma Inc. (KNTE) Climb 305% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Kinnate Biopharma Inc. (KNTE) points to a 305% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6432 seconds.